In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
BUSINESS
Will Ilaris Remain an “Ultra-orphan” Drug?
Ilaris (canakinumab; Novartis Pharma), the first treatment for cryopyrin-associated periodic syndrome (CAPS) to receive approval in Japan, was added to the NHI price list in late November 2011. Ilaris has been launched in 21 countries and regions to date. In…
To read the full story
BUSINESS
- Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
November 5, 2025
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Maruho, Nielsen Ink Licensing Deal for Common Warts Therapy in Asia
November 5, 2025
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…